Brokerage firm in hot water again after regulator dolls out fine after underwriting a now-troubled landscaping construction company in 2018

Guangdong government establishes special purpose vehicle to stave off collapse of leading drugs manufacturer saddled with 33.3 billion yuan of debt

Company briefly went into a technical default as funds arrived late at clearing house

Zhou Xitai, a former Communist Party committee member of a state-owned asset manager, is set to take over as GF’s top political official

Scandal-plagued, debt-ridden drugmaker’s shares suspended for two days in Shanghai pending major development to be announced by parent company

Brokerage ditched by longtime partner as joint lead underwriter for 15 billion yuan private placement

Brokerage house is banned from sponsoring listings for six months and from bond underwriting for a year as CSRC singles out 14 individuals for punishment

Ma Xingtian suspected of directing drugmaker’s $12.6 billion financial fraud from 2016‒2018 involving fake bank deposits, forged business documents and illicit share trading

Scandal-marred pharmaceutical company’s auditor also raises questions about several figures in its latest annual report

Lin Zhihai was responsible for GF’s work with disgraced Kangmei Pharmaceutical and helped set up a hedge fund that lost 900 million yuan

Kangmei admitted Saturday that it moved $1.3 billion through affiliated companies to buy its own stock